Compliance Rate

Compliance Rate 0%
Compliant submissions 0
Incompliant submissions 0
Total trials 0

My Organizations' Clinical Trials

Showing 7 of 7 entries
View as:

A Study to Evaluate the Safety and Efficacy of Celgosivir and Peginterferon Alfa-2b, With or Without Ribavirin, in Patients With Chronic Hepatitis C Genotype 1 Infection

Phase: N/A Priority: Normal
NCT ID: NCT00217139 Org: User:
Start: 09/30/05 End: 09/30/06 Due: 09/30/07

A Study to Evaluate the Safety and Efficacy of Celgosivir in Patients With Chronic Hepatitis C Genotype 1 Infection

Phase: N/A Priority: Normal
NCT ID: NCT00157534 Org: User:
Start: 10/31/04 End: 08/31/05 Due: 08/31/06

An Extension Study to Evaluate the Safety and Efficacy of Celgosivir and Peginterferon Alfa-2b, With or Without Ribavirin, in Patients With Chronic Hepatitis C Genotype 1 Infection

Phase: N/A Priority: Normal
NCT ID: NCT00292084 Org: User:
Start: 02/28/06 End: 10/31/07 Due: 10/31/08

Safety and Efficacy of MBI 226 2.5% and 5.0% Topical Acne Solutions in the Treatment of Acne

Phase: N/A Priority: Normal
NCT ID: NCT00211523 Org: User:
Start: 10/31/00 End: 09/30/01 Due: 09/30/02

Safety and Efficacy of MBI 226 1.25% and 2.5% Topical Acne Solutions in the Treatment of Acne

Phase: N/A Priority: Normal
NCT ID: NCT00211497 Org: User:
Start: 01/31/03 End: 09/30/03 Due: 09/30/04

A Study to Evaluate the Safety, Antiviral Effect, and Pharmacokinetics of Celgosivir in Combination With Peginterferon Alfa-2b and Ribavirin in Treatment-Naïve Patients With Chronic Hepatitis C

Phase: N/A Priority: Normal
NCT ID: NCT00332176 Org: User:
Start: 06/30/06 End: 12/31/08 Due: 12/31/09

Safety and Efficacy of MBI 226 for the Prevention of Central Venous Catheter-Related Bloodstream Infections

Phase: N/A Priority: Normal
NCT ID: NCT00027248 Org: User:
Start: 09/30/00 End: 07/31/03 Due: 07/31/04